Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Lin YJ;Lin YJ; Lee MH; Yang HI; Jen CL; You SL; Wang LY; Lu SN; Liu J; Chen CJ
  • Source:
    PloS one [PLoS One] 2013 Apr 17; Vol. 8 (4), pp. e61448. Date of Electronic Publication: 2013 Apr 17 (Print Publication: 2013).
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Biomarkers, Tumor/*blood ; Carcinoma, Hepatocellular/*blood ; Carcinoma, Hepatocellular/*etiology ; Hepatitis B, Chronic/*complications ; Liver/*metabolism ; Liver Neoplasms/*blood ; Liver Neoplasms/*etiology; Adult ; Area Under Curve ; Carcinoma, Hepatocellular/epidemiology ; Cohort Studies ; Female ; Hepatitis B, Chronic/epidemiology ; Humans ; Incidence ; Liver Neoplasms/epidemiology ; Male ; Middle Aged ; Multivariate Analysis ; Proportional Hazards Models ; ROC Curve ; Reproducibility of Results ; Risk Factors
    • Abstract:
      Background: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is a major global health problem. A few risk calculators have been developed using mainly HBV seromarkers as predictors. However, serum HBV DNA level, HBV genotype, and mutants are not routinely checked in regular health examinations. This study aimed to assess the predictability of HCC risk in chronic hepatitis B patients, using a combination of liver-related seromarkers combined with or without HBV seromarkers.
      Methods: A prospective cohort of 1,822 anti-HCV-seronegative chronic HBV carriers was included in this study. Liver-related seromarkers including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alpha-fetoprotein (AFP), gamma-glutamyltransferase (GGT), total bilirubin, total protein, albumin, serum globulins, apolipoprotein A1, and apolipoprotein B were examined. Hazard ratios of HCC with 95% confidence intervals were estimated using Cox proportional hazards regression models. Regression coefficients of seromarkers significantly associated with HCC risk in multivariate analyses were used to create integer risk scores. The predictability of various risk models were assessed by area under receiver operating characteristic curves (AUROCs).
      Results: During a median follow-up of 5.9 years, 48 newly-developed HCC cases were ascertained. Elevated serum levels of ALT (≥ 28 U/L), AFP (≥ 5 ng/mL), and GGT (≥ 41 U/L), an increased AST/ALT ratio (AAR, ≥ 1), and lowered serum levels of albumin (≤ 4.1 g/dL) and alpha-1 globulin (≤ 0.2 g/dL) were significantly associated with an increased HCC risk (P<0.05) in multivariate analysis. The risk model incorporating age, gender, AAR, and serum levels of ALT, AFP, GGT, albumin, and alpha-1 globulin had an AUROC of 0.89 for predicting 6-year HCC incidence. The AUROC was 0.91 after the addition of HBV seromarkers into the model, and 0.83 for the model without liver-related seromarkers, with the exception of ALT.
      Conclusion: Liver-related seromarkers may be combined into useful risk models for predicting HBV-related HCC risk.
    • References:
      Arch Intern Med. 2003 Jan 27;163(2):218-24. (PMID: 12546613)
      Gastroenterology. 2012 May;142(6):1264-1273.e1. (PMID: 22537432)
      N Engl J Med. 1986 Mar 20;314(12):736-9. (PMID: 3485248)
      JAMA. 2006 Jan 4;295(1):65-73. (PMID: 16391218)
      J Hepatol. 2012 Dec;57(6):1326-35. (PMID: 22750749)
      Cancer. 1983 Jan 15;51(2):327-31. (PMID: 6185200)
      BMC Gastroenterol. 2011 Aug 17;11:91. (PMID: 21849046)
      J Hepatol. 2009 Jan;50(1):80-8. (PMID: 18977053)
      J Hepatol. 2012 Aug;57(2):442-50. (PMID: 22504333)
      Antivir Ther. 2007;12(8):1295-303. (PMID: 18240869)
      J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. (PMID: 21323729)
      Gastroenterology. 2006 Mar;130(3):678-86. (PMID: 16530509)
      Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96. (PMID: 15508108)
      Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. (PMID: 15508101)
      N Engl J Med. 2002 Jul 18;347(3):168-74. (PMID: 12124405)
      J Clin Oncol. 2010 May 10;28(14):2437-44. (PMID: 20368541)
      N Engl J Med. 2004 Oct 7;351(15):1521-31. (PMID: 15470215)
      Gut. 2004 Oct;53(10):1494-8. (PMID: 15361502)
      Lancet. 2001 Apr 7;357(9262):1069-75. (PMID: 11297957)
      Liver Int. 2008 Dec;28(10):1408-16. (PMID: 18482268)
      Vaccine. 2012 Mar 9;30(12):2212-9. (PMID: 22273662)
      J Clin Oncol. 2010 Apr 1;28(10):1660-5. (PMID: 20194845)
      Lancet. 2005 Apr 23-29;365(9469):1500-5. (PMID: 15850636)
      Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58. (PMID: 20628345)
      Hepatology. 2009 May;49(5 Suppl):S72-84. (PMID: 19399801)
      Biometrics. 1988 Sep;44(3):837-45. (PMID: 3203132)
      J Hepatol. 2001 Sep;35(3):421-30. (PMID: 11592607)
      Gastroenterology. 2003 Feb;124(2):327-34. (PMID: 12557138)
      Stat Med. 2004 May 30;23(10):1631-60. (PMID: 15122742)
      Lancet Oncol. 2011 Jun;12(6):568-74. (PMID: 21497551)
    • Accession Number:
      0 (Biomarkers, Tumor)
    • Publication Date:
      Date Created: 20130425 Date Completed: 20131111 Latest Revision: 20220408
    • Publication Date:
      20231215
    • Accession Number:
      PMC3629190
    • Accession Number:
      10.1371/journal.pone.0061448
    • Accession Number:
      23613855